Clinical and Operational PET opportunities
Prostate-Specific Membrane Antigen, PSMA, PET imaging
Over 200,0001 cases of Prostate Cancer per year are diagnosed in the US.
New emerging theranostic-enabling agents could help redefine cancer therapy.*
New PSMA-targeted PET tracers, indicated for use in patients with suspected prostate cancer metastasis or recurrence, have been approved by the FDA.
Download Cartesion Prime Flyer
Clinical results may vary due to clinical setting, patient presentation and other factors.